Caribou Biosciences Inc (NASDAQ:CRBU) shares, rose in value, with the stock price up by 4.55% to the previous day’s close as strong demand from buyers drove the stock to $1.15.
Actively observing the price movement in the last trading, the stock closed the session at $1.10. Referring to stock’s 52-week performance, its high was $7.74, and the low was $1.01. On the whole, CRBU has fluctuated by -16.06% over the past month.
With the market capitalization of Caribou Biosciences Inc currently standing at about $104.14 million, investors are eagerly awaiting this quarter’s results, scheduled for in April.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 1.84M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CRBU’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of CRBU currently trading nearly -10.51% and -21.68% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 35.82, while the 7-day volatility ratio is showing 8.60% which for the 30-day chart, stands at 7.09%. Furthermore, Caribou Biosciences Inc (CRBU)’s beta value is 2.32, and its average true range (ATR) is 0.10.
A comparison of Caribou Biosciences Inc (CRBU) with its peers suggests the former has fared considerably weaker in the market. CRBU showed an intraday change of 4.55% in last session, and over the past year, it shrunk by -85.24%%. In comparison, Bristol Myers Squibb Co. (BMY) has moved higher at 0.64%% on the day and was up 12.06% over the past 12 months. On the other hand, the price of CRISPR Therapeutics AG (CRSP) has risen 0.90%% on the day. The stock, however, is off -45.76% from where it was a year ago. Additionally, there is a loss of -1.25%% for Beam Therapeutics Inc. (BEAM) in last trading while the stock has seen an overall depriciation of -31.79%% over the past year.
Data on historical trading for Caribou Biosciences Inc (NASDAQ:CRBU) indicates that the trading volumes over the past 3 months, they’ve averaged 1.39 million. According to company’s latest data on outstanding shares, there are 90.55 million shares outstanding.
Nearly 13.11% of Caribou Biosciences Inc’s shares belong to company insiders and institutional investors own 60.34% of the company’s shares. The stock has fallen by -27.67% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CRBU stock heading into the next quarter.
